针对GBA1和LRRK2的治疗:前进的道路
Gadi Maayan Eshed1, Roy N Alcalay2
1Movement Disorders Division, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
Parkinsonism & related disorders
|March 4, 2024
概括
基因定义的药物标显示出对帕金森病 (PD) 治疗的希望. 临床试验正在探索葡萄糖大脑酶-1 (GBA1) 和富含白的重复激酶2 (LRRK2) 途径的疾病修饰.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 需要新的治疗策略来改变疾病.
- 基因定义的药物标为开发有效的PD治疗提供了有希望的途径.
- 目前的研究重点是葡萄糖大脑蛋白酶-1 (GBA1) 和富含白的重复激酶2 (LRRK2) 基因.
研究的目的:
- 审查基因定义的PD药物标的潜力.
- 要突出正在进行的针对GBA1和LRRK2通路的临床试验.
- 为了确定路径修改和患者分层的关键知识差距.
主要方法:
- 对PD中GBA1和LRRK2的当前文献的综述.
- 对GBA1和LRRK2.的正在进行的临床试验策略的分析.
- 讨论机械学见解和生物标记数据.
主要成果:
- 临床试验正在积极调查GBA1和LRRK2通路.
- 干预的目的是增加葡萄糖大脑酶 (GCase) 活性 (GBA1) 或减少激酶活性 (LRRK2).
- 生物标志物数据表明,在零星的PD患者中,GBA1向疗法的潜力.
结论:
- 预计PD的精准医学将取得重大进展.
- 需要进一步研究以了解机制并优化患者选择.
- 有基因信息的方法有望改变PD的进展.
更多相关视频
11:31Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
10.0K
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.5K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
